65,437 trials
Malignant Melanoma
Primary: T 1/2 — 9.94 hr
Hypertension
Primary: Change From Double-blind Baseline (Week 26) in Sitting Clinic Diastolic Blood Pressure to Week 32 — 0.14; 7.92 mmHg — p=<0.001
Healthy
Primary: Area Under the Concentration-Time Curve From Zero Time Until the Last Sampling Time (AUCt) — 126.36; 129.48; 122.33; 119.75 ng*h/mL
Onychomycosis
Primary: Clinical and Mycological Cure of Target Toenail — 22.3; 1 Percentage of participants — p=<0.001
Sickle Cell Disease
Primary: Number of Serious Adverse Events — 6; 9; 0; 0 events
Hypertension
Primary: Changes in Mean Blood Pressure (Systolic) After Treatment, Compared to Baseline — -30.71; -30.32; -30.35; -30.73 mmHg
Astigmatism
Primary: Correction of Astigmatism — -0.54; -0.59 diopter — p=<0.05
Friedreich's Ataxia
Primary: Change in the International Cooperative Ataxia Rating Scale (ICARS) From Baseline Assessment to Week 24 — -2.5; -2.4; -1.3 ICARS points
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -0.857; -0.871 percentage (%) of total haemoglobin
Chronic Hepatitis C
Primary: Percent of Participants Who Were Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Negative at the End of Treatment (EoT) — 35.0; 6.3; 16.3; 13.4 Percent of participants
Type 2 Diabetes Mellitus
Primary: Preservation of Beta-cell Function Measured by Area-under-the-curve (C-peptide/Glucose)/HOMA-IR — 80.4; 71.2 index of beta-cell function
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Lung Function as Measured by the Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0-3h (AUC0-3h) — -0.06; 0.16 litres *…
Multiple Myeloma
Primary: Number of Patients With Combined Complete Response and Very Good Partial Response — 21; 23; 13; 9 participants
Migraine
Primary: Overall Satisfaction — 73.7 Scale of 0-100; 100= very satisfied — p=0.0007
Gastroesophageal Reflux
Primary: Maximum Observed Plasma Concentration (Cmax) — 136; 798; 1643; 2067 nanogram per milliliter (ng/mL)